Mice that their imaged signals reached around 2 × 108 p/s were thereafter enrolled as positive HCC-bearing mice and then randomized into three groups and intravenously treated with: PBS, Ad-ΔB, and Ad-ΔB/TRAIL+Ad-ΔB/IL-12, respectively, at a dosage schedule of 1 × 1010 VP of each vector/injection; three times with two days interval. This evidence concerns the gene TNFSF10 and hepatocellular carcinoma.